Compare BCYC & BLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCYC | BLW |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.6M | 533.4M |
| IPO Year | 2019 | N/A |
| Metric | BCYC | BLW |
|---|---|---|
| Price | $6.83 | $13.86 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $18.73 | N/A |
| AVG Volume (30 Days) | ★ 244.7K | 85.9K |
| Earning Date | 10-30-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.83% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.81 |
| Revenue | ★ $28,339,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.73 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.03 | $12.35 |
| 52 Week High | $15.47 | $14.26 |
| Indicator | BCYC | BLW |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 56.51 |
| Support Level | $6.73 | $13.72 |
| Resistance Level | $7.28 | $13.85 |
| Average True Range (ATR) | 0.33 | 0.07 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 11.96 | 80.95 |
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Blackrock Ltd Duration Income Trust is a diversified investment fund with an investment objective to provide current income and capital appreciation. The Fund's portfolio normally has an average portfolio duration of less than five years. The Fund may invest directly in such securities or synthetically through the use of derivatives.